CLIFF (Cordlife Group) Buyback Yield %: 0.00 (As of Jul. 01, 2026)


CLIFF Cordlife Group Ltd CLIFF
41 GF Score
Price $0.15
GF Value $0.08
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cordlife Group Buyback Yield %?

Cordlife Group CLIFF 41 Buyback Yield % is 0.00 as of Jul. 01, 2026. GuruFocus rates CLIFF with a GF Score™ of 41/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 89 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 1123594.38% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Cordlife Group's current buyback yield was 0.00%.


Cordlife Group Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Cordlife Group's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cordlife Group Buyback Yield % Chart

Cordlife Group Annual Data
Trend Jun15 Jun16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cordlife Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CLIFF vs TMO, DHR, IDXX: Buyback Yield % Comparison

For the Diagnostics & Research subindustry, Cordlife Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cordlife Group Buyback Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Cordlife Group's Buyback Yield % falls into.


CLIFF
41GF Score
Cordlife Group Ltd CLIFF
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cordlife Group Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Cordlife Group's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 17.6596212
=0.00%

Cordlife Group's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 18.0440832
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Cordlife Group (CLIFF) has a Buyback Yield % of 0.00 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cordlife Group and its competitors. According to the industry distribution chart, Cordlife Group ranks #999999 out of 89 companies in the Medical Diagnostics & Research industry.
Is Cordlife Group's Buyback Yield % too high?
Cordlife Group's current Buyback Yield % is 0.00. Based on the distribution chart, Cordlife Group ranks #999999 out of 89 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Cordlife Group has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #999999 out of 89 companies for Buyback Yield %. This places Cordlife Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cordlife Group and its competitors. Cordlife Group's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current Buyback Yield % is 0.00. Cordlife Group's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current Buyback Yield % is 0.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cordlife Group (CLIFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued. The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08. GuruFocus considers Cordlife Group to be Significantly Overvalued.

Key valuation signals for CLIFF:

  • Buyback Yield %: 0.00
  • GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cordlife Group Business Description

Other Exchanges P8A:Singapore
Address 1 Kim Seng Promenade, No. 15-01, Great World City East, Singapore, SGP, 237994
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
41GF Score

Get the complete analysis for CLIFF

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.08
GF Value